Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.

Clinical and molecular hepatology - 1 Mar 2017

Seo Kwang Il, Yun Byung Chul, Li Weiquan James, Lee Sang Uk, Han Byung Hoon, Park Eun Taek

Abstract excerpt

BACKGROUND/AIMS: Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been used to treat chronic hepatitis C without severe adverse effects and have achieved a sustained viral response (SVR) rate of 80-90% with short treatment duration. We were interested to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Recurrence

Share to RNA, Viral

Source

Open in PubMed Open full text

Identifiers

PMID: 28259115
DOI: 10.3350/cmh.2016.0052
PMCID: PMC5381840

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.PMID 28259115Read ↗

Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era.Semantic proximity Read ↗

Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.Semantic proximity Read ↗

A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapiesSemantic proximity Read ↗

Direct-Acting Antiviral Agents: Regimens for the Interferon Failure Patient.Semantic proximity Read ↗

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity Read ↗

Management of untreated and nonresponder patients with chronic hepatitis C.Semantic proximity Read ↗

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Semantic proximity Read ↗

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV eliminationSemantic proximity Read ↗

Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.Semantic proximity Read ↗

Hepatitis C infection: eligibility for antiviral therapies.Semantic proximity Read ↗

Barriers in Hepatitis C Treatment in Somali Patients in the Direct Acting Antiviral Therapy Era.Semantic proximity Read ↗

Treatment failure with new hepatitis C drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.